Ketchum Public Relations is to co-ordinate communications for the global
launch of anti-depressant prescription drug Remeron.
Remeron’s manufacturers Organon signed up Ketchum PR’s healthcare
division two weeks ago after seeing it pitch against healthcare
specialist Shire Hall Communications.
The campaign, which is believed to be worth an estimated pounds 150,000
in fees, will target psychiatrists and GPs throughout the world. The
launch will kick off in the Netherlands and Finland.
The agency is planning to liaise with local agencies in each country,
reaching potential audiences through a combination of specialist media
and professional relations activities.
Remeron is a hybrid of the two existing classes of anti-depressant
medicines; the strong tri-cyclic drugs which are prone to side-effects
and the milder division of Selective Seratonin Re-uptake Inhibitors
‘We will work closely with experts to ensure psychiatrists and GP’s
understand the difference with the new class,’ said Paul Blackburn,
director of Ketchum PR’s healthcare arm. ‘Remeron is potent, but it has
minimal side effects,’ he added.
Other clients handled by Ketchum’s five-strong healthcare division
include Abbott Laboratories and Rhone Poulenc-Rorer.